Transforming Growth Factor-β and Breast Cancer Risk in Women With Mammary Epithelial Hyperplasia
Open Access
- 15 December 1999
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 91 (24) , 2096-2101
- https://doi.org/10.1093/jnci/91.24.2096
Abstract
BACKGROUND: Transforming growth factors-β (TGF-βs) regulate mammary epithelial cell division. Loss of expression of TGF-β receptor II (TGF-β-RII) is related to cell proliferation and tumor progression. Breast epithelial hyperplastic lesions lacking atypia (EHLA) are associated with a mild elevation in breast cancer risk. We investigated the expression of TGF-β-RII in EHLA and the risk of subsequent invasive breast cancer. METHODS: We conducted a nested case-control study of women with biopsy-confirmed EHLA who did not have a history of breast cancer or atypical hyperplasia of the breast. Case patients (n = 54) who subsequently developed invasive breast cancer were matched with control patients (n = 115) who did not. Formalin-fixed, paraffin-embedded sections of breast biopsy specimens of all 169 patients with EHLA were studied by immunohistochemical analysis with antibodies against TGF-β-RII. All P values are two-sided. RESULTS: Women with breast EHLA and 25%-75% TGF-β-RII-positive cells or less than 25% TGF-β-RII-positive cells had odds ratios of invasive breast cancer of 1.98 (95% confidence interval [CI] = 0.95-4.1) or 3.41 (95% CI = 1.2-10.0), respectively (P for trend = .008). These risks are calculated with respect to women with EHLA that had greater than 75% TGF-β-RII expression. Women with a heterogeneous pattern of TGF-β-RII expression in their normal breast lobular units and either greater than 75%, 25%-75%, or less than 25% positive cells in their EHLA had odds ratios for breast cancer risk of 0.742 (95% CI = 0.3-1.8), 2.85 (95% CI = 1.1-7.1), or 3.55 (95% CI = 1.0-10.0), respectively (P for trend = .003). These risks are relative to women with a homogeneous pattern of expression in their normal lobular units and greater than 75% positive cells in their EHLA. CONCLUSION: This study indicates that loss of TGF-β-RII expression in epithelial cells of EHLA is associated with increased risk of invasive breast cancer.Keywords
This publication has 32 references indexed in Scilit:
- Expression of transforming growth factor-β receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cellsJournal of Cellular Physiology, 1998
- Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma developmentOncogene, 1998
- The multifunctional role of transforming growth factor (TGF)-ßs on mammary epithelial cell biologyBreast Cancer Research and Treatment, 1996
- Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesionsNature Medicine, 1995
- Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite InstabilityScience, 1995
- Mechanism of activation of the TGF-β receptorNature, 1994
- Long-Term Risk of Breast Cancer in Women with FibroadenomaNew England Journal of Medicine, 1994
- Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.Journal of Clinical Investigation, 1993
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Risk Factors for Breast Cancer in Women with Proliferative Breast DiseaseNew England Journal of Medicine, 1985